比较动态血糖监测与血糖监测在接受胰岛素治疗且控制不佳的2型糖尿病成人中的效果(Steno2tech研究):一项为期12个月的单中心随机对照试验
这项单中心、平行、开放标签随机对照试验纳入76例接受胰岛素治疗且HbA1c≥7.5%的2型糖尿病成人,随机分入动态血糖监测(CGM)组或血糖监测(BGM)组干预12个月。与BGM相比,CGM在目标范围内时间(TIR)、HbA1c、每日胰岛素总量、体重、BMI及自我评定的糖尿病相关健康、幸福感、满意度和健康行为方面均带来显著更大改善。
要点
- CGM组TIR改善较BGM组高15.2%(95%CI 4.6;25.9)。
- CGM组HbA1c较BGM组多降低0.9%(95%CI -1.4;-0.3)。
- CGM组每日胰岛素总量较BGM组多减少10.6单位/天(95%CI -19.9;-1.3)。
核心结论
- 在接受胰岛素治疗且控制不佳的2型糖尿病成人中,CGM使用12个月在改善血糖控制及其他关键健康指标方面优于BGM。
- 研究结果支持在2型糖尿病的胰岛素治疗亚组中使用CGM。
研究设计与样本
- 单中心、平行、开放标签随机对照试验,纳入来自丹麦Steno糖尿病中心门诊的接受胰岛素治疗且控制不佳的2型糖尿病成人。
- 纳入标准为年龄≥18岁、接受胰岛素治疗的2型糖尿病且HbA1c≥7.5%(58 mmol/mol)。
- 参与者按1:1随机分配至12个月CGM或BGM,所有参与者接受糖尿病自我管理教育课程并由其常规医疗保健提供者随访。
- 主要结局为通过盲法CGM在基线、6个月和12个月评估的3.9-10.0 mmol/L目标范围内时间(TIR)变化的组间差异。
- 共76例参与者,基线HbA1c中位数为8.3(7.8,9.1)%(67[62-76] mmol/mol),61.8%为男性。
主要发现
- 与BGM相比,CGM使用与TIR改善显著更大相关(组间差异15.2%,95%CI 4.6;25.9)。
- 与BGM相比,CGM使用与HbA1c降低显著更大相关(组间差异-0.9%,95%CI -1.4;-0.3[-9.4 mmol/mol,-15.2;-3.5])。
- 与BGM相比,CGM使用与每日胰岛素总量减少显著更大相关(组间差异-10.6单位/天,95%CI -19.9;-1.3)。
- 与BGM相比,CGM使用与体重降低显著更大相关(组间差异-3.3 kg,95%CI -5.5;-1.1)及BMI降低显著更大相关(组间差异-1.1 kg/m2,95%CI -1.8;-0.3)。
- 与BGM相比,CGM使用与自我评定的糖尿病相关健康、幸福感、满意度和健康行为改善更大相关。
临床怎么用
- 原文结论指出研究结果支持在2型糖尿病的胰岛素治疗亚组中使用CGM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the 12-month effects of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) in adults with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS: This is a single-center, parallel, open-label, randomized controlled trial including adults with inadequately controlled, insulin-treated type 2 diabetes from the outpatient clinic at Steno Diabetes Center Copenhagen, Denmark. Inclusion criteria were ≥18 years of age, insulin-treated type 2 diabetes, and HbA1c ≥7.5% (58 mmol/mol). Participants were randomly assigned (1:1) to 12 months of either CGM or BGM. All participants received a diabetes self-management education course and were followed by their usual health care providers. Primary outcome was between-group differences in change in time in range (TIR) 3.9-10.0 mmol/L, assessed at baseline, after 6 and 12 months by blinded CGM. The prespecified secondary outcomes were differences in change in several other glycemic, metabolic, and participant-reported outcomes. RESULTS: The 76 participants had a median baseline HbA1c of 8.3 (7.8, 9.1)% (67 [62-76] mmol/mol), and 61.8% were male. Compared with BGM, CGM usage was associated with significantly greater improvements in TIR (between-group difference 15.2%, 95% CI 4.6; 25.9), HbA1c (-0.9%, -1.4; -0.3 [-9.4 mmol/mol, -15.2; -3.5]), total daily insulin dose (-10.6 units/day, -19.9; -1.3), weight (-3.3 kg, -5.5; -1.1), and BMI (-1.1 kg/m2, -1.8; -0.3) and greater self-rated diabetes-related health, well-being, satisfaction, and health behavior. CONCLUSIONS: In adults with inadequately controlled insulin-treated type 2 diabetes, the 12-month impact of CGM was superior to BGM in improving glucose control and other crucial health parameters. The findings support the use of CGM in the insulin-treated subgroup of type 2 diabetes.
引用
- Lind N, Christensen MB, Hansen DL, et al. Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial. Diabetes Care. 2024. PMID: 38489032. doi:10.2337/dc23-2194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。